Biocytogen 

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/hCD40 mice


Basic characteristics

1.png


Targeting strategy


2.png

Protein expression analysis

1544169548663593.png

Fig 1. Splenocytes from homozygous B-hPD-1/hCD40 mice were analyzed by flow cytometry.

mCD40+ cells were detectable in wild type (WT) C57BL/6, hCD40+ cells were detectable in the homozygous B-hPD-1/hCD40 mice.


1544169666101159.png

Fig 2. Splenocytes from homozygous B-hPD-1/hCD40 mice were analyzed by flow cytometry.

mPD-1+ cells were detectable in wild type (WT) C57BL/6, hPD-1+ cells were detectable in the homozygous

B-hPD-1/hCD40 mice.


Antibody efficacy evaluation


1.png

Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=8). Anti-hCD40 antibody Selicrelumab Analog and the anti-hPD-1 antibody Keytruda show modest inhibition of tumor growth. On the other hand, combination of Selicrelumab Analog and Keytruda shows significantly inhibition when compared to single Ab treatment. B-hPD-1/hCD40 mouse model is a powerful tool for in vivo evaluation of combination therapy efficacy for hPD-1 antibodies and hCD40 antibodies . (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.



【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud